HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
|
carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
tegafur/uracil Sensitive: C3 – Early Trials
|
tegafur / uracil Sensitive: C3 – Early Trials
|
HR negative
|
Hormone Receptor Negative Breast Cancer
|
HR negative
|
Hormone Receptor Negative Breast Cancer
|
TCHP Sensitive: C3 – Early Trials
|
TCHP Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
pertuzumab Sensitive: C3 – Early Trials
|
pertuzumab Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
AMG 479 Sensitive: C3 – Early Trials
|
AMG 479 Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
pembrolizumab + pertuzumab + Trazimera (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
pembrolizumab + pertuzumab + Trazimera (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
trastuzumab + pyrotinib Sensitive: C3 – Early Trials
|
trastuzumab + pyrotinib Sensitive: C3 – Early Trials
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C4 – Case Studies
|
ado-trastuzumab emtansine Sensitive: C4 – Case Studies
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
CDK19 inhibitor Sensitive: D – Preclinical
|
CDK19 inhibitor Sensitive: D – Preclinical
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
CDK8 inhibitor Sensitive: D – Preclinical
|
CDK8 inhibitor Sensitive: D – Preclinical
|
HR negative
|
HER2 Positive Breast Cancer
|
HR negative
|
HER2 Positive Breast Cancer
|
RVU120 Sensitive: D – Preclinical
|
RVU120 Sensitive: D – Preclinical
|